Afabicin clinical trials
Also written Debio 1450.
How each study uses afabicin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the afabicin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses afabicin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Renal Impairment Pharmacokinetics (PK) Trial of AfabicinRecruitingPhase 1Debiopharm International SANCT07758608Written as Afabicin Oral
- Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to StaphylococcusTerminatedPhase 2Debiopharm International SANCT03723551Written as Afabicin
- Study of Debio 1450 for Bacterial Skin InfectionsCompletedPhase 2Debiopharm International SANCT02426918Written as Debio 1450 IV
- A Study to Investigate the Effect of Itraconazole on the Pharmacokinetics of Debio 1450 in Healthy SubjectsCompletedPhase 1Debiopharm International SANCT03209648Written as Debio 1450
- Drug Penetration Into Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement SurgeryCompletedPhase 1Debiopharm International SANCT02726438Written as Debio 1450
- A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy VolunteersCompletedPhase 1Debiopharm International SANCT02214433Written as Debio 1450 IV Solution
- A Single Dose Study of Debio 1450 in Healthy SubjectsCompletedPhase 1Debiopharm International SANCT02162199Written as Debio 1450
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
- Renal Impairment Pharmacokinetics (PK) Trial of AfabicinOct 26, 2026NCT07758608
Codes
What other systems call afabicin · ClinicalTrials.gg INT001261
- MeSH (NLM) C000657127afabicinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) DMM8663H2RAFABICINConfirmed FDA, NLM, Wikidata
- Wikidata Q27276486afabicinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C169766AfabicinOne source FDA
- DrugBank DB15268One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000657127 | afabicin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | DMM8663H2R | AFABICIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27276486 | afabicin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C169766 | Afabicin | One source FDA |
| DrugBank | DB15268 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.